Cytovia Commits to Additional Milestones and Equity grant
AVENTURA, Fla. and NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) — Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited iNK (NK cells derived from iPSC)…
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China
Share this article
More News
Price Targets For Bitcoin, Ethereum and XRP
April 10, 2026
Is a $1,000 Target Realistic?
April 10, 2026
Crypto yields are falling below TradFi
April 10, 2026